 |
市场调查报告书
商品编码
1608839
眼部发炎治疗市场：按药物类别、按剂型、按分销管道、按地区Eye Inflammation Treatment Market, By Drug Class, By Dosage Form, By Distribution Channel, By Geography |
||||||
眼部发炎治疗市场预计到2024年将达到6.219亿美元，预计到2031年将达到9.268亿美元，2024年至2031年的复合年增长率为5.9%。
| 报告范围 | 报告详情 | ||
|---|---|---|---|
| 基准年 | 2023年 | 2024年市场规模 | 6.219 亿美元 |
| 实际资料 | 2019-2023 | 预测期 | 2024年至2031年 |
| 预测 2024-2031 年复合年增长率： | 5.90% | 2031年价值预测 | 9.268 亿美元 |
眼部发炎，又称眼科疾病，是指眼睛肿胀或发炎。它通常是由感染疾病、过敏或其他疾病引起的。易患与老龄化相关的眼部疾病的老年人口不断增加、全球结膜炎患者患病率不断增加以及新产品的推出可能会推动对眼部发炎治疗药物和设备的需求。药物传递和缓释性的进步提高了治疗效果和患者依从性。新治疗方案的高成本和重磅药物的专利到期是市场成长的挑战。对新药和药物器材联合治疗的持续研究可能会提供市场成长机会。
市场动态
眼部发炎治疗市场的成长是由于结膜炎和葡萄膜炎等眼部发炎盛行率的增加、影响眼睛健康的过敏和自体免疫疾病发病率的增加以及新药的发布带来的疗效的提高所推动的。然而，生物製药和细胞疗法的高成本可能会阻碍市场成长。利用药物和药物输送装置的联合治疗的开拓、生物相似药的出现以及新兴市场的扩张可能为市场参与者提供成长机会。重磅药物的专利到期和新眼科产品核准的严格法律规范可能会阻碍市场成长。
本研究的主要特点
该报告对全球眼部发炎治疗市场进行了详细分析，并提供了以2023年为基准年的预测期（2024-2031年）的市场规模（百万美元）和年复合成长率（CAGR%）。
它还揭示了各个细分市场的潜在商机，并说明了该市场有吸引力的投资提案矩阵。
它还提供了有关市场驱动因素、限制因素、机会、新产品发布和核准、市场趋势、区域前景、主要企业采取的竞争策略等的重要见解。
根据公司亮点、产品系列、主要亮点、业绩和策略等参数，提供全球眼部发炎治疗市场主要企业的概况。
本研究涵盖的主要企业包括 GSK plc.、Merck &Co.Inc.、Alimera Sciences, Inc.、AbbVie Inc.、Teva Pharmaceutical Industries Ltd.、Akron Pharma Inc.、Intas Pharmaceuticals Ltd.、Mylan NV、Amgen Inc.、辉瑞公司、麦克劳兹製药有限公司等。
该报告的见解使负责人和公司经营团队能够就未来的产品发布、类型升级、市场扩张和行销策略做出明智的决策。
全球眼部发炎治疗市场报告针对该行业的各个相关人员，如投资者、供应商、产品製造商、经销商、新进业者和财务分析师。
透过用于分析全球眼部发炎治疗市场的各种策略矩阵，将有助于相关人员做出决策。
目录
第一章 研究目的与前提
- 研究目的
- 先决条件
- 简称
第二章 市场展望
- 报告说明
- 市场定义和范围
- 执行摘要
第三章 市场动态、法规与趋势分析
- 市场动态
- 影响分析
- 主要亮点
- 监管场景
- 产品发布/核准
- PEST分析
- 波特分析
- 併购场景
- 流行病学
- 管道分析
第四章 眼部发炎治疗市场，依药物类别，2019-2031
- 皮质类固醇
- 抗生素
- 单株抗体
- 抗真菌药物
- 睫状肌麻痹药
- 其他的
第五章 眼部发炎治疗市场，按剂型，2019-2031
- 眼药水
- 药片
- 胶囊
- 其他的
第六章眼部发炎治疗市场，依通路，2019-2031
- 医院药房
- 零售药房
- 网路药房
第七章 2019-2031 年眼部发炎治疗市场（按地区）
- 北美洲
- 拉丁美洲
- 欧洲
- 亚太地区
- 中东
- 非洲
第八章 竞争格局
- GSK plc.
- Merck & Co. Inc.
- Alimera Sciences, Inc.
- AbbVie Inc.
- Teva Pharmaceutical Industries Ltd.
- Akron Pharma Inc.
- Intas Pharmaceuticals Ltd.
- Mylan NV
- Amgen Inc.
- Pfizer Inc.
- Macleods Pharmaceuticals Ltd.
第九章 分析师建议
- 命运之轮
- 分析师观点
- 一致的机会图
第10章 参考文献与调查方法
- 参考
- 调查方法
- 关于出版商
Eye inflammation treatment market is estimated to be valued at USD 621.9 Mn in 2024 and is expected to reach USD 926.8 Mn by 2031, exhibiting a compound annual growth rate (CAGR) of 5.9% from 2024 to 2031.
| Report Coverage | Report Details | ||
|---|---|---|---|
| Base Year: | 2023 | Market Size in 2024: | 621.9 Mn |
| Historical Data for: | 2019 to 2023 | Forecast Period: | 2024 to 2031 |
| Forecast Period 2024 to 2031 CAGR: | 5.90% | 2031 Value Projection: | 926.8 Mn |
Eye inflammation, also known as ophthalmia, refers to the swelling and irritation of the eyes. It is usually caused by infections, allergies or other medical conditions. Rising geriatric population susceptible to age-related ocular disorders, growing prevalence of conjunctivitis cases worldwide and new product launches can boost demand for eye inflammation drugs and devices. Advancements in drug delivery methods and sustained release formulations have improved treatment effectiveness and patient compliance. High costs of newer treatment options and patent expiries of blockbuster drugs pose challenges for the market growth. Ongoing research on novel drugs and drug-device combination therapies can offer market growth opportunities.
Market Dynamics
Eye inflammation treatment market growth is driven by growing prevalence of eye inflammations like conjunctivitis and uveitis, increasing incidence of allergies and autoimmune diseases affecting eye health, and launch of newer drugs with improved efficacy. However, high costs of biologics and cell therapy can hamper the market growth. Development of combination therapies utilizing drugs and drug delivery devices, emergence of biosimilars, and expansion in emerging economies can offer growth opportunities for market players. Patent expiries of blockbuster drugs and stringent regulatory framework for approval of new ophthalmic products can hamper the market growth.
Key features of the study
This report provides in-depth analysis of the global eye inflammation treatment market, and provides market size (USD Mn) and compound annual growth rate (CAGR%) for the forecast period (2024-2031), considering 2023 as the base year
It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
It profiles key players in the global eye inflammation treatment market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
Key companies covered as a part of this study include GSK plc., Merck & Co. Inc., Alimera Sciences, Inc., AbbVie Inc., Teva Pharmaceutical Industries Ltd., Akron Pharma Inc., Intas Pharmaceuticals Ltd., Mylan N.V., Amgen Inc., Pfizer Inc., and Macleods Pharmaceuticals Ltd.
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
Global eye inflammation treatment market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global eye inflammation treatment market
Market Segmentation
- By Drug Class Insights (Revenue, USD Mn, 2019 - 2031)
- Corticosteroids
- Antibiotics
- Monoclonal Antibodies
- Antifungals
- Cycloplegic Agents
- Others
- By Dosage Form Insights (Revenue, USD Mn, 2019 - 2031)
- Eye Drops
- Tablets
- Capsules
- Others
- By Distribution Channel Insights (Revenue, USD Mn, 2019 - 2031)
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- By Regional Insights (Revenue, USD Mn, 2019 - 2031)
- North America
- U.S.
- Canada
- Latin America
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- South Africa
- North Africa
- Central Africa
- Key Players Insights
- GSK plc.
- Merck & Co. Inc.
- Alimera Sciences, Inc.
- AbbVie Inc.
- Teva Pharmaceutical Industries Ltd.
- Akron Pharma Inc.
- Intas Pharmaceuticals Ltd.
- Mylan N.V.
- Amgen Inc.
- Pfizer Inc.
- Macleods Pharmaceuticals Ltd.
Table of Contents
1. Research Objectives and Assumptions
- Research Objectives
- Assumptions
- Abbreviations
2. Market Purview
- Report Description
- Market Definition and Scope
- Executive Summary
- Eye Inflammation Treatment Market, By Drug Class
- Eye Inflammation Treatment Market, By Dosage Form
- Eye Inflammation Treatment Market, By Distribution Channel
- Eye Inflammation Treatment Market, By Region
3. Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Impact Analysis
- Key Highlights
- Regulatory Scenario
- Product Launches/Approvals
- PEST Analysis
- PORTER's Analysis
- Merger and Acquisition Scenario
- Epidemiology
- Pipeline Analysis
4. Eye Inflammation Treatment Market, By Drug Class, 2019-2031, (USD Mn)
- Introduction
- Market Share Analysis, 2024 and 2031 (%)
- Y-o-Y Growth Analysis, 2020 - 2031
- Segment Trends
- Corticosteroids
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Mn)
- Antibiotics
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Mn)
- Monoclonal Antibodies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Mn)
- Antifungals
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Mn)
- Cycloplegic Agents
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Mn)
- Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Mn)
5. Eye Inflammation Treatment Market, By Dosage Form, 2019-2031, (USD Mn)
- Introduction
- Market Share Analysis, 2024 and 2031 (%)
- Y-o-Y Growth Analysis, 2020 - 2031
- Segment Trends
- Eye Drops
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Mn)
- Tablets
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Mn)
- Capsules
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Mn)
- Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Mn)
6. Eye Inflammation Treatment Market, By Distribution Channel, 2019-2031, (USD Mn)
- Introduction
- Market Share Analysis, 2024 and 2031 (%)
- Y-o-Y Growth Analysis, 2020 - 2031
- Segment Trends
- Hospital Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Mn)
- Retail Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Mn)
- Online Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Mn)
7. Eye Inflammation Treatment Market, By Region, 2019 - 2031, (USD Mn)
- Introduction
- Market Share (%) Analysis, 2024,2027 & 2031, (USD Mn)
- Market Y-o-Y Growth Analysis (%), 2020 - 2031, (USD Mn)
- Regional Trends
- North America
- Introduction
- Market Size and Forecast, By Drug Class, 2019 - 2031, (USD Mn)
- Market Size and Forecast, By Dosage Form, 2019 - 2031, (USD Mn)
- Market Size and Forecast, By Distribution Channel, 2019 - 2031, (USD Mn)
- Market Size and Forecast, By Country, 2019 - 2031, (USD Mn)
- U.S.
- Canada
- Latin America
- Introduction
- Market Size and Forecast, By Drug Class, 2019 - 2031, (USD Mn)
- Market Size and Forecast, By Dosage Form, 2019 - 2031, (USD Mn)
- Market Size and Forecast, By Distribution Channel, 2019 - 2031, (USD Mn)
- Market Size and Forecast, By Country, 2019 - 2031, (USD Mn)
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Introduction
- Market Size and Forecast, By Drug Class, 2019 - 2031, (USD Mn)
- Market Size and Forecast, By Dosage Form, 2019 - 2031, (USD Mn)
- Market Size and Forecast, By Distribution Channel, 2019 - 2031, (USD Mn)
- Market Size and Forecast, By Country, 2019 - 2031, (USD Mn)
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- Introduction
- Market Size and Forecast, By Drug Class, 2019 - 2031, (USD Mn)
- Market Size and Forecast, By Dosage Form, 2019 - 2031, (USD Mn)
- Market Size and Forecast, By Distribution Channel, 2019 - 2031, (USD Mn)
- Market Size and Forecast, By Country, 2019 - 2031, (USD Mn)
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- Introduction
- Market Size and Forecast, By Drug Class, 2019 - 2031, (USD Mn)
- Market Size and Forecast, By Dosage Form, 2019 - 2031, (USD Mn)
- Market Size and Forecast, By Distribution Channel, 2019 - 2031, (USD Mn)
- Market Size and Forecast, By Country, 2019 - 2031, (USD Mn)
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- Introduction
- Market Size and Forecast, By Drug Class, 2019 - 2031, (USD Mn)
- Market Size and Forecast, By Dosage Form, 2019 - 2031, (USD Mn)
- Market Size and Forecast, By Distribution Channel, 2019 - 2031, (USD Mn)
- Market Size and Forecast, By Country/Region, 2019 - 2031, (USD Mn)
- South Africa
- North Africa
- Central Africa
8. Competitive Landscape
- GSK plc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Merck & Co. Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Alimera Sciences, Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- AbbVie Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Teva Pharmaceutical Industries Ltd.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Akron Pharma Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Intas Pharmaceuticals Ltd.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Mylan N.V.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Amgen Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Pfizer Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Macleods Pharmaceuticals Ltd.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
9. Analyst Recommendations
- Wheel of Fortune
- Analyst View
- Coherent Opportunity Map
10. References and Research Methodology
- References
- Research Methodology
- About us
